Cannabidiol is a negative allosteric modulator of the cannabinoid CB 1 receptor

Cited by (1,000)

Items 301–400 of 1,000

1. Current and Potential Use of Biologically Active Compounds Derived from Cannabis sativa L. in the Treatment of Selected Diseases
   Bożena Bukowska · 2024 · International Journal of Molecular Sciences
2. Interactions between cannabidiol and Δ9-THC following acute and repeated dosing: Rebound hyperactivity, sensorimotor gating and epigenetic and neuroadaptive changes in the mesolimbic pathway
   Stephanie M. Todd, Cilla Zhou, David J. Clarke, Tariq W. Chohan, Dilara Bahceci, Jonathon Carl Arnold · 2017 · European Neuropsychopharmacology
3. Cannabidiol regulates behavioural alterations and gene expression changes induced by spontaneous cannabinoid withdrawal
   Francisco Navarrete, A. Aracil-Fernández, Jorge Manzanares · 2018 · British Journal of Pharmacology
4. Allosteric Modulators Targeting Cannabinoid cb1 and cb2 Receptors: Implications for Drug Discovery
   Francesca Gado, Serena Meini, Simone Bertini, Maria Digiacomo, Marco Macchia, Clementina Manera · 2019 · Future Medicinal Chemistry
5. The Impact of Perioperative Cannabis Use: A Narrative Scoping Review
   Karim Shiraz Ladha, Varuna Manoo, Ali-Faizan Virji, John G. Hanlon, Alexander McLaren-Blades, Akash Goel, Duminda Nalaka Wijeysundera, Lakshmi P. Kotra, Carlos A Ibarra, Marina F Englesakis et al. · 2019 · Cannabis and Cannabinoid Research
6. Crosstalk between the M1 muscarinic acetylcholine receptor and the endocannabinoid system: A relevance for Alzheimer's disease?
   Karen J. Thompson, Andrew B. Tobin · 2020 · Cellular Signalling
7. A single dose of cannabidiol modulates medial temporal and striatal function during fear processing in people at clinical high risk for psychosis
   Cathy Davies, Robin Paul Wilson, Elizabeth Appiah‐Kusi, Grace Blest‐Hopley, Michael John Brammer, Jesús Pérez, Robin M. Murray, Paul Allen, Matthijs Geert Bossong, Philip K. McGuire et al. · 2020 · Translational Psychiatry
8. The endocannabinoid system – current implications for drug development
   Christopher John Fowler · 2020 · Journal of Internal Medicine
9. Clinical Outcome Data of First Cohort of Chronic Pain Patients Treated With Cannabis‐Based Sublingual Oils in the United Kingdom: Analysis From the UK Medical Cannabis Registry
   Michal Kawka, Simon Erridge, Carl Holvey, Ross Coomber, Azfer Usmani, Mohammad Sajad, Michael W. Platt, James Rucker, Mikael Hans Sodergren · 2021 · The Journal of Clinical Pharmacology
10. The acute effects of cannabis with and without cannabidiol in adults and adolescents: A randomised, double‐blind, placebo‐controlled, crossover experiment
    Will Lawn, Katie Trinci, Claire Mokrysz, Anna Borissova, Shelan Ofori, Kat Petrilli, Michael Bloomfield, Zarah R. Haniff, Daniel Hall, Natalia Fernandez‐Vinson et al. · 2023 · Addiction
11. Psychosocial and pharmacological interventions for the treatment of cannabis use disorder
    Sabioni, Pamela, Le Foll, Bernard · 2018 · F1000Research
12. Pharmacokinetic Variability of Oral Cannabidiol and Its Major Metabolites after Short-Term High-Dose Exposure in Healthy Subjects
    Qingchen Zhang, Philip W Melchert, John Seth Markowitz · 2024 · Medical Cannabis and Cannabinoids
13. Cannabinoids and the Microbiota–Gut–Brain Axis: Emerging Effects of Cannabidiol and Potential Applications to Alcohol Use Disorders
    Hollis C. Karoly, Raeghan L. Mueller, L. Cinnamon Bidwell, Kent E. Hutchison · 2019 · Alcoholism Clinical and Experimental Research
14. Phytocannabinoids and schizophrenia: Focus on adolescence as a critical window of enhanced vulnerability and opportunity for treatment
    Tibor Štark, Serena Di Martino, Filippo Drago, Carsten Tobias Wotjak, Vincenzo Micale · 2021 · Pharmacological Research
15. Inflammation and Nitro-oxidative Stress as Drivers of Endocannabinoid System Aberrations in Mood Disorders and Schizophrenia
    Gerwyn Morris, Luba Sominsky, Kenneth R. Walder, Michael Berk, Wolfgang Marx, Andre Ferrer Carvalho, Chiara C. Bortolasci, Michael H. J. Maes, Basant K. Puri · 2022 · Molecular Neurobiology
16. Factors that Impact the Pharmacokinetic and Pharmacodynamic Effects of Cannabis: a Review of Human Laboratory Studies
    Carlos Austin Zamarripa, Ryan G. Vandrey, Tory R. Spindle · 2022 · Current Addiction Reports
17. Sex Differences in the Neuropsychiatric Effects and Pharmacokinetics of Cannabidiol: A Scoping Review
    Justin Matheson, Zoe Bourgault, Bernard Le Foll · 2022 · Biomolecules
18. Adverse effects of heavy cannabis use: Even plants can harm the brain
    Sideli, Lucia, Trotta, Giulia, Spinazzola, Edoardo, La Cascia, Caterina, Di Forti, Marta · 2021 · Pain
19. The Role of Cannabidiol in Liver Disease: A Systemic Review
    Si Chen, Jeon-Kyung Kim · 2024 · International Journal of Molecular Sciences
20. Targeting CB1 and GPR55 Endocannabinoid Receptors as a Potential Neuroprotective Approach for Parkinson’s Disease
    Eva Martínez‐Pinilla, David Aguinaga, Gemma Navarro, Alberto J. Rico, Julen Oyarzábal, Juan Antonio Sánchez-Arias, José Luis Lanciego, Rafael Franco · 2019 · Molecular Neurobiology
21. Synergistic cytotoxic activity of cannabinoids fromcannabis sativaagainst cutaneous T-cell lymphoma (CTCL)in-vitroandex-vivo
    Moran Mazuz, Amir Tiroler, Lilach Moyal, Emmilia Hodak, Stalin Nadarajan, A. C. Vinayaka, Batia Gorovitz, Ido Lubin, Avi Drori, Guy Drori et al. · 2020 · Oncotarget
22. Phytocannabinoids: General Aspects and Pharmacological Potential in Neurodegenerative Diseases
    Graziella dos Reis Rosa Franco, Scott Darryl Smid, Cláudio Viegas · 2020 · Current Neuropharmacology
23. Understanding the Medical Chemistry of the Cannabis Plant is Critical to Guiding Real World Clinical Evidence
    Karim Shiraz Ladha, Prabjit Ajrawat, Yi Yang, Hance A. Clarke · 2020 · Molecules
24. Synaptic changes induced by cannabinoid drugs and cannabis use disorder
    Shana M. Augustin, David M. Lovinger · 2022 · Neurobiology of Disease
25. The Basic Science of Cannabinoids
    Alexandra Sideris, Justas Lauzadis, Martin Kaczocha · 2023 · Anesthesia & Analgesia
26. Seeing through the smoke: Human and animal studies of cannabis use and endocannabinoid signalling in corticolimbic networks
    Mason M. Silveira, Jonathon Carl Arnold, Steven R. Laviolette, Cecilia J. Hillard, Marta Celorrio, María S. Aymerich, Wendy K. Adams · 2016 · Neuroscience & Biobehavioral Reviews
27. Cannabis containing equivalent concentrations of delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) induces less state anxiety than THC-dominant cannabis
    Nadia R. P. W. Hutten, Thomas R. Arkell, Frederick R. J. Vinckenbosch, Jan Schepers, Richard C. Kevin, Eef Lien Theunissen, Kim P. C. Kuypers, Iain S. McGregor, Johannes Gerardus Ramaekers · 2022 · Psychopharmacology
28. Assessment of clinical outcomes of medicinal cannabis therapy for depression: analysis from the UK Medical Cannabis Registry
    Sajed Mangoo, Simon Erridge, Carl Holvey, Ross Coomber, Daniela A. Riaño Barros, Urmila Bhoskar, Gracia Mwimba, Kavita Praveen, Chris Symeon, Simmi Sachdeva-Mohan et al. · 2022 · Expert Review of Neurotherapeutics
29. Beyond Pain Relief: A Review on Cannabidiol Potential in Medical Therapies
    Mariana Veiga, João Azevedo‐Silva, João Carlos Fernandes · 2023 · Pharmaceuticals
30. Cannabidiolic acid exhibits entourage-like improvements of anticonvulsant activity in an acute rat model of seizures
    Brett Goerl, Sarah J. Watkins, Cameron S. Metcalf, Misty D. Smith, Mark P. Beenhakker · 2020 · Epilepsy Research
31. Female but not male rats show biphasic effects of low doses of Δ9-tetrahydrocannabinol on anxiety: can cannabidiol interfere with these effects?
    Beatriz Zanutto Salviato, Ana Maria Raymundi, Thiago Rodrigues da Silva, Bruna Wuilleumier Salemme, Jeferson Machado Batista Sohn, Fabiano Soares de Araujo, Francisco Silveira Guimarães, Leandro Jose Bertoglio, Cristina Aparecida Jark Stern · 2021 · Neuropharmacology
32. The Impact of Early Life Exposure to Cannabis: The Role of the Endocannabinoid System
    Annia A. Martínez-Peña, Genevieve A. Perono, Sarah Alexis Gritis, Reeti Sharma, Shamini Selvakumar, O’Llenecia S. Walker, Harmeet Gurm, Alison C. Holloway, Sandeep Raha · 2021 · International Journal of Molecular Sciences
33. The state-of-the-art pharmacotherapeutic options for the treatment of chronic non-cancer pain
    Ryan Steven D'Souza, Brendan J Langford, Rachel E. Wilson, Yeng F Her, Justin B. Schappell, Jennifer S. Eller, Timothy C. Evans, Jonathan Michael Hagedorn · 2022 · Expert Opinion on Pharmacotherapy
34. Cannabinoid CB1 receptors regulate salivation
    Kelsey Andreis, Jenna Billingsley, Kian Naimi Shirazi, Jim Wager‐Miller, Clare T. Johnson, Heather B. Bradshaw, Alex J. Straiker · 2022 · Scientific Reports
35. Cannabinoids in Late Life Parkinson’s Disease and Dementia: Biological Pathways and Clinical Challenges
    Alana C. Costa, Helena Passarelli Giroud Joaquim, João Francisco Cordeiro Pedrazzi, Andréia de Oliveira Pain, Gustavo Duque, Iván Aprahamian · 2022 · Brain Sciences
36. Cannabinoids: Revealing their complexity and role in central networks of fear and anxiety
    Anthony Murkar, Joseph De Koninck, Zul Merali · 2021 · Neuroscience & Biobehavioral Reviews
37. Skin applications of cannabidiol: sources, effects, delivery systems, marketed formulations and safety
    Beatriz P. Ferreira, Gustavo Costa, Filipa Mascarenhas‐Melo, Patrícia C. Pires, Fariba Heidarizadeh, Prabhanjan Shridhar Giram, Priscila Gava Mazzola, Célia Cabral, Francisco Veiga, Ana Cláudia Paiva‐Santos · 2023 · Phytochemistry Reviews
38. Prenatal tetrahydrocannabinol and cannabidiol exposure produce sex-specific pathophysiological phenotypes in the adolescent prefrontal cortex and hippocampus
    Marieka V. DeVuono, Mina G. Nashed, Mohammed Halit Sarikahya, Andrea Kocsis, Kendrick Lee, Sebastian Vanin, Roger Hudson, Eryn P. Lonnee, Walter J. Rushlow, Daniel Barry Hardy et al. · 2024 · Neurobiology of Disease
39. Possible therapeutic applications of cannabis in the neuropsychopharmacology field
    Javier Fernández‐Ruíz, Ismael Galve‐Roperh, Onintza Sagredo, Manuel Guzmán · 2020 · European Neuropsychopharmacology
40. The Pro-neurogenic Effects of Cannabidiol and Its Potential Therapeutic Implications in Psychiatric Disorders
    M. Luján, O. Valverde · 2020 · Frontiers in Behavioral Neuroscience
41. Cannabis, Cannabinoids, and Brain Morphology: A Review of the Evidence
    Yann Chye, Rebecca Kirkham, Valentina Lorenzetti, Eugene McTavish, Nadia Solowij, Murat Yücel · 2020 · Biological Psychiatry Cognitive Neuroscience and Neuroimaging
42. Distinctive Evidence Involved in the Role of Endocannabinoid Signalling in Parkinson’s Disease: A Perspective on Associated Therapeutic Interventions
    Tapan Behl, Gagandeep Kaur, SIMONA GABRIELA BUNGAU, Rishabh Jhanji, Arun Kumar, Vineet Mehta, Gökhan Zengin, Roxana Daniela Brata, Syed Shams ul Hassan, Ovidiu Frățilă · 2020 · International Journal of Molecular Sciences
43. An update of nano-based drug delivery systems for cannabinoids: Biopharmaceutical aspects & therapeutic applications
    Elisa Regina Lazzarotto Rebelatto, Gabriela Schneider Rauber, Thiago Caon · 2023 · International Journal of Pharmaceutics
44. A systematic review of cannabidiol trials in neurodevelopmental disorders
    Nina-Francesca Parrella, Aron T. Hill, Peter G. Enticott, Pamela Barhoun, Isabella Simone Bower, Talitha C. Ford · 2023 · Pharmacology Biochemistry and Behavior
45. Cannabitwinol, a Dimeric Phytocannabinoid from Hemp, Cannabis sativa L., Is a Selective Thermo-TRP Modulator
    Giuseppina Chianese, Annalisa Lopatriello, Aniello Schiano Moriello, Diego Caprioglio, Daiana Mattoteia, Emanuele Benetti, Daniele Ciceri, Lolita Arnoldi, Eric De Combarieu, Rosa Maria Vitale et al. · 2020 · Journal of Natural Products
46. Cannabidiol Modulates Behavioural and Gene Expression Alterations Induced by Spontaneous Cocaine Withdrawal
    Ani Gasparyan, Francisco Navarrete, Marta Rodríguez‐Arias, José Miñarro, Jorge Manzanares · 2020 · Neurotherapeutics
47. Cannabinoids: a class of unique natural products with unique pharmacology
    Fabiana Piscitelli, Vincenzo Di Marzo · 2021 · RENDICONTI LINCEI
48. Cannabinoids, reward processing, and psychosis
    Brandon Gunasekera, Kelly M. J. Diederen, Sagnik Bhattacharyya · 2021 · Psychopharmacology
49. Cannabidiol (CBD) Use by Older Adults for Acute and Chronic Pain
    Brooke Porter, Barbara St. Marie, Gary Milavetz, Keela Herr · 2021 · Journal of Gerontological Nursing
50. Neuroprotective potential of cannabidiol: Molecular mechanisms and clinical implications
    Srushti M. Tambe, Suraj N. Mali, Purnima Dhanraj Amin, Mozaniel Santana de Oliveira · 2023 · Journal of Chinese Integrative Medicine
51. Negative allosteric modulators of cannabinoid receptor 2: protein modeling, binding site identification and molecular dynamics simulations in the presence of an orthosteric agonist
    Pankaj Pandey, Kuldeep Kumar Roy, Robert J. Doerksen · 2019 · Journal of Biomolecular Structure and Dynamics
52. Efficacy of Δ9 -Tetrahydrocannabinol (THC) Alone or in Combination With a 1:1 Ratio of Cannabidiol (CBD) in Reversing the Spatial Learning Deficits in Old Mice
    Prakash Nidadavolu, András Bilkei‐Gorzó, Michael Krämer, Britta Schürmann, Michela Palmisano, Eva Carolina Beins, B Madea, Andreas Zimmer · 2021 · Frontiers in Aging Neuroscience
53. Increased expression of cannabinoid CB2 and serotonin 5-HT1A heteroreceptor complexes in a model of newborn hypoxic-ischemic brain damage
    Rafael Franco, Maria Pia Villa, Paula Morales, Irene Reyes‐Resina, Ana Gutiérrez‐Rodrίguez, Jasmina Jiménez, Nadine Jagerovic, José Antonio Martínez-Orgado, Gemma Navarro · 2019 · Neuropharmacology
54. Calcium-Sensing Receptor Internalization Is β-Arrestin–Dependent and Modulated by Allosteric Ligands
    Iris Mos, Stine Engesgaard Jacobsen, Simon Richard Foster, Hans Bräuner‐Osborne · 2019 · Molecular Pharmacology
55. Cannabinoid Receptors in Metabolic Regulation and Diabetes
    Elisabeth Rohbeck, Jürgen Eckel, Tania Romacho · 2021 · Physiology
56. Development of cannabidiol nanoemulsion for direct nose to brain delivery: statistical optimization, in vitro and in vivo evaluation
    Bakr Ahmed, Md. Rizwanullah, Showkat Rasool Mir, Mohammad Shaheer Akhtar, Saima Amin · 2022 · Biomedical Materials
57. Characterization of cannabinoid plasma concentration, maternal health, and cytokine levels in a rat model of prenatal Cannabis smoke exposure
    Tallan Black, Sarah L. Baccetto, Ilne L. Barnard, Emma Finch, Dan L. McElroy, Faith V. L. Austin-Scott, Quentin Greba, Deborah L. Michel, Ayat Zagzoog, John G. Howland et al. · 2023 · Scientific Reports
58. Cannabidiol modulation of antinociceptive tolerance to Δ9-tetrahydrocannabinol
    Nicholas Z. Greene, Jenny L. Wiley, Zhihao Yu, Brian H. Clowers, Rebecca M. Craft · 2018 · Psychopharmacology
59. Pain response to cannabidiol in induced acute nociceptive pain, allodynia, and hyperalgesia by using a model mimicking acute pain in healthy adults in a randomized trial (CANAB I)
    Tobias Schneider, Laura Zurbriggen, Markus Dieterle, Eckhard Mauermann, Priska Frei, Katja Mercer‐Chalmers‐Bender, Wilhelm Ruppen · 2021 · Pain
60. Cannabinoids and Chronic Liver Diseases
    Ralph‐Sydney Mboumba Bouassa, Giada Sebastiani, Vincenzo Di Marzo, Mohammad-Ali Jenabian, Cecilia Theresa Costiniuk · 2022 · International Journal of Molecular Sciences
61. Targeting Neuroinflammation as Disease Modifying Approach to Alzheimer’s Disease: Potential and Challenges
    Smita Jain, Ritu Singh, Sarvesh Paliwal, Swapnil K. Sharma · 2023 · Mini-Reviews in Medicinal Chemistry
62. Hydrophobic Ligand Entry and Exit Pathways of the CB1 Cannabinoid Receptor
    Jakub Jakowiecki, Sławomir Filipek · 2016 · Journal of Chemical Information and Modeling
63. A comparative study of supercritical fluid and ethanol extracts of cannabis inflorescences: Chemical profile and biological activity
    Fernández, Santiago, Carreras, Tatiana, Castro, Rossina, Perelmuter, Karen, Giorgi, Victoria, Vila, Agustina, Rosales, Agustina, Pazos, Mariana, Moyna, Guillermo, Carrera, Ignacio et al. · 2022 · The Journal of Supercritical Fluids
64. Integrated multi-class classification and prediction of GPCR allosteric modulators by machine learning intelligence
    Hou, Tianling, Bian, Yuemin, McGuire, Terence, Xie, Xiang-Qun · 2021 · Biomolecules
65. Natural allosteric modulators and their biological targets: molecular signatures and mechanisms
    Marjorie Bruder, Gina Polo, Daniela Barretto Barbosa Trivella · 2020 · Natural Product Reports
66. Chronic Cannabidiol Administration Attenuates Skeletal Muscle De Novo Ceramide Synthesis Pathway and Related Metabolic Effects in a Rat Model of High-Fat Diet-Induced Obesity
    Patrycja Bielawiec, Ewa Harasim‐Symbor, Karolina Konstantynowicz-Nowicka, Klaudia Sztolsztener, Adrian Chabowski · 2020 · Biomolecules
67. Similarities and differences upon binding of naturally occurring Δ9-tetrahydrocannabinol-derivatives to cannabinoid CB1 and CB2 receptors
    Iu Raïch, Rafael Rivas‐Santisteban, Alejandro Lillo, Jaume Lillo, Irene Reyes‐Resina, Xavier Nadal, Carlos Ferreiro‐Vera, Verónica Sánchez de Medina, María Majellaro, Eddy Sotelo et al. · 2021 · Pharmacological Research
68. The endocannabinoid system in migraine: from bench to pharmacy and back
    Cristina Tassorelli, Rosaria Greco, Stephen David Silberstein · 2019 · Current Opinion in Neurology
69. In silicomapping of allosteric ligand binding sites in type‐1 cannabinoid receptor
    Annalaura Sabatucci, Daniel Tortolani, Enrico Dainese, Mauro Maccarrone · 2017 · Biotechnology and Applied Biochemistry
70. The future of type 1 cannabinoid receptor allosteric ligands
    Mariam Alaverdashvili, Robert B. Laprairie · 2018 · Drug Metabolism Reviews
71. Cannabidiol prevents priming- and stress-induced reinstatement of the conditioned place preference induced by cocaine in mice
    Claudia Calpe-López, Ani Gasparyan, Francisco Navarrete, Jorge Manzanares, José Miñarro, M.A. Aguilar · 2021 · Journal of Psychopharmacology
72. At the intersection of sleep deficiency and opioid use: mechanisms and therapeutic opportunities
    Mark K. Greenwald, Tabitha E.H. Moses, Timothy Roehrs · 2021 · Translational research
73. Shared Biological Pathways between Antipsychotics and Omega-3 Fatty Acids: A Key Feature for Schizophrenia Preventive Treatment?
    Ariel Frajerman, Linda Scoriels, Oussama Kébir, Boris Chaumette · 2021 · International Journal of Molecular Sciences
74. Potentiation of microglial endocannabinoid signaling alleviates neuroinflammation in Alzheimer's disease
    Deepthi Rapaka, Veera Raghavulu Bitra, Siva Reddy Challa, Paul Chukwuemeka Adiukwu · 2021 · Neuropeptides
75. Enhancing Endocannabinoid Control of Stress with Cannabidiol
    Jeremy David Henson, Luis Vitetta, Michelle Quezada, Sean Hall · 2021 · Journal of Clinical Medicine
76. The dose-dependent effect of a stabilized cannabidiol nanoemulsion on ocular surface inflammation and intraocular pressure
    Leslie Rebibo, Marina Frušić‐Zlotkin, Ron Ofri, Taher Nassar, Simon Benita · 2022 · International Journal of Pharmaceutics
77. Receptor mechanisms underlying the CNS effects of cannabinoids: CB1 receptor and beyond
    Briana J. Hempel, Zheng‐Xiong Xi · 2022 · Advances in pharmacology
78. Biosynthetic origins of unusual cannabimimetic phytocannabinoids in Cannabis sativa L: A review
    Matthew T. Welling, Myrna A. Deseo, Antony Bacic, Monika S. Doblin · 2022 · Phytochemistry
79. Emotional disorders induced by Hemopressin and RVD-hemopressin(α) administration in rats
    Sheila Leone, Lucia Recinella, Annalisa Chiavaroli, Sara Martinotti, Claudio Ferrante, Adriano Mollica, Giorgia Macedonio, Azzurra Stefanucci, Szabolcs Dvorácskó, Csaba Tömböly et al. · 2017 · Pharmacological Reports
80. Cannabidiol and Cannabigerol, Nonpsychotropic Cannabinoids, as Analgesics that Effectively Manage Bone Fracture Pain and Promote Healing in Mice
    Deepak Kumar Khajuria, Vengadeshprabhu Karuppagounder, Irena Nowak, Diana E. Sepúlveda, Gregory S. Lewis, Christopher C. Norbury, Wesley M. Raup‐Konsavage, Kent E. Vrana, Fadia Kamal, Reyad A. Elbarbary · 2023 · Journal of Bone and Mineral Research
81. The Effect of Orally Administered Δ9-Tetrahydrocannabinol (THC) and Cannabidiol (CBD) on Obesity Parameters in Mice
    Adi Eitan, Ofer Gover, Liron Sulimani, David Meiri, Betty Schwartz · 2023 · International Journal of Molecular Sciences
82. Effects of Cannabinoids on Intestinal Motility, Barrier Permeability, and Therapeutic Potential in Gastrointestinal Diseases
    Kijan Crowley, Łukasz Kiraga, Edyta Miszczuk, S. Skiba, Joanna Banach, Urszula Latek, Marta Mendel, Magdalena Chłopecka · 2024 · International Journal of Molecular Sciences
83. CBD and the 5-HT1A receptor: A medicinal and pharmacological review
    Claire Alexander, Jiyoon Jeon, Kyle Nickerson, Shayne N. Hassler, Maryam Vasefi · 2025 · Biochemical Pharmacology
84. Barriers to the wider adoption of medicinal Cannabis
    S P H Alexander · 2020 · British Journal of Pain
85. CB1 allosteric modulators and their therapeutic potential in CNS disorders
    Catharine A. Mielnik, Vincent M. Lam, Ruth A. Ross · 2020 · Progress in Neuro-Psychopharmacology and Biological Psychiatry
86. Repurposing Cannabidiol as a Potential Drug Candidate for Anti-Tumor Therapies
    Fei Wang, Gabriele Multhoff · 2021 · Biomolecules
87. The endocannabinoid system, cannabis, and cannabidiol: Implications in urology and men's health
    J. Capodice, S. Kaplan · 2021 · Current Urology
88. Cannabis and Autoimmunity: Possible Mechanisms of Action
    Valeria Giorgi, Daniela Marotto, Alberto Batticciotto, Fabiola Atzeni, Sara Francesca Bongiovanni, Piercarlo Sarzi‐Puttini · 2021 · ImmunoTargets and Therapy
89. Comprehensive inventory of cannabinoids in Cannabis sativa L.: Can we connect genotype and chemotype?
    Bernd Markus Lange, Jordan J. Zager · 2021 · Phytochemistry Reviews
90. Pain response to cannabidiol in opioid-induced hyperalgesia, acute nociceptive pain, and allodynia using a model mimicking acute pain in healthy adults in a randomized trial (CANAB II)
    Markus Dieterle, Laura Zurbriggen, Eckhard Mauermann, Katja Mercer‐Chalmers‐Bender, Priska Frei, Wilhelm Ruppen, Tobias Schneider · 2022 · Pain
91. Phytocannabinoid drug-drug interactions and their clinical implications
    Daniela Amaral Silva, David W. Pate, Robert D. Clark, Neal M. Davies, Ayman O.S. El‐Kadi, Raimar Löbenberg · 2020 · Pharmacology & Therapeutics
92. Behavioral and Molecular Effects Induced by Cannabidiol and Valproate Administration in the GASH/Sal Model of Acute Audiogenic Seizures
    Giselda Cabral-Pereira, David Sánchez-Benito, Sandra M. Díaz-Rodríguez, Jaime Gonçalves-Sánchez, Consuelo Sancho, Orlando Castellano, Luis J. Muñoz, Dolores E. López, Ricardo Gómez‐Nieto · 2021 · Frontiers in Behavioral Neuroscience
93. Cannabinoid Modulation of Dopamine Release During Motivation, Periodic Reinforcement, Exploratory Behavior, Habit Formation, and Attention
    Erik B. Oleson, Lindsey R. Hamilton, Devan M. Gomez · 2021 · Frontiers in Synaptic Neuroscience
94. Cannabidiol Attenuates MK-801-Induced Cognitive Symptoms of Schizophrenia in the Passive Avoidance Test in Mice
    Marta Kruk-Słomka, Grażyna Biała · 2021 · Molecules
95. CBD‐mediated regulation of heroin withdrawal‐induced behavioural and molecular changes in mice
    Francisco Navarrete, Ani Gasparyan, Jorge Manzanares · 2022 · Addiction Biology
96. Cannabidiol markedly alleviates skin and liver fibrosis
    Carmen del Río, Francisco Ruíz-Pino, María E. Prados, Bernd L. Fiebich, Manuel Tena‐Sempere, Eduardo Muñóz · 2022 · Frontiers in Pharmacology
97. Assessment of clinical outcomes in patients with post-traumatic stress disorder: analysis from the UK Medical Cannabis Registry
    Manaswini Pillai, Simon Erridge, Lara Bapir, Martha Nicholas, Nishaanth Dalavaye, Carl Holvey, Ross Coomber, Daniela A. Riaño Barros, Urmila Bhoskar, Gracia Mwimba et al. · 2022 · Expert Review of Neurotherapeutics
98. Role of the endocannabinoid system in fragile X syndrome: potential mechanisms for benefit from cannabidiol treatment
    Joseph Palumbo, Brian F. Thomas, Dejan B. Budimirovic, Steven J. Siegel, Flora Tassone, Randi Jenssen Hagerman, Christopher D. Faulk, Stephen O’Quinn, Terri B. Sebree · 2023 · Journal of Neurodevelopmental Disorders
99. Δ9-Tetrahydrocannabinol decreases willingness to exert cognitive effort in male rats
    Mason M. Silveira, Wendy K. Adams, Maria Morena, Matthew N. Hill, Catharine A. Winstanley · 2017 · Journal of Psychiatry and Neuroscience
100. Hippocampal mammalian target of rapamycin is implicated in stress-coping behavior induced by cannabidiol in the forced swim test
     Ariandra Guerini Sartim, Amanda J. Sales, Francisco Silveira Guimarães, Sâmia R.L. Joca · 2018 · Journal of Psychopharmacology